CERS
Price
$1.78
Change
-$0.00 (-0.00%)
Updated
Dec 13, 10:33 AM (EDT)
69 days until earnings call
XAIR
Price
$0.48
Change
-$0.00 (-0.00%)
Updated
Dec 12, 04:59 PM (EDT)
55 days until earnings call
Ad is loading...

CERS vs XAIR

Header iconCERS vs XAIR Comparison
Open Charts CERS vs XAIRBanner chart's image
Cerus
Price$1.78
Change-$0.00 (-0.00%)
Volume$5.14K
CapitalizationN/A
Beyond Air
Price$0.48
Change-$0.00 (-0.00%)
Volume$1.23K
CapitalizationN/A
CERS vs XAIR Comparison Chart
Loading...
CERS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XAIR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CERS vs. XAIR commentary
Dec 13, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CERS is a Hold and XAIR is a Sell.

COMPARISON
Comparison
Dec 13, 2024
Stock price -- (CERS: $1.78 vs. XAIR: $0.49)
Brand notoriety: CERS and XAIR are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: CERS: 54% vs. XAIR: 64%
Market capitalization -- CERS: $342.62M vs. XAIR: $79.87M
CERS [@Medical Specialties] is valued at $342.62M. XAIR’s [@Medical Specialties] market capitalization is $79.87M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.02B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CERS’s FA Score shows that 0 FA rating(s) are green whileXAIR’s FA Score has 1 green FA rating(s).

  • CERS’s FA Score: 0 green, 5 red.
  • XAIR’s FA Score: 1 green, 4 red.
According to our system of comparison, both CERS and XAIR are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CERS’s TA Score shows that 4 TA indicator(s) are bullish while XAIR’s TA Score has 3 bullish TA indicator(s).

  • CERS’s TA Score: 4 bullish, 6 bearish.
  • XAIR’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, both CERS and XAIR are a bad buy in the short-term.

Price Growth

CERS (@Medical Specialties) experienced а +2.30% price change this week, while XAIR (@Medical Specialties) price change was -1.73% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +0.76%. For the same industry, the average monthly price growth was -0.44%, and the average quarterly price growth was +1.96%.

Reported Earning Dates

CERS is expected to report earnings on Feb 20, 2025.

XAIR is expected to report earnings on Feb 06, 2025.

Industries' Descriptions

@Medical Specialties (+0.76% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CERS($343M) has a higher market cap than XAIR($79.9M). CERS YTD gains are higher at: -17.593 vs. XAIR (-75.143). CERS has higher annual earnings (EBITDA): -26.34M vs. XAIR (-67.06M). CERS has more cash in the bank: 65.9M vs. XAIR (31.3M). XAIR has less debt than CERS: XAIR (16.9M) vs CERS (96M). CERS has higher revenues than XAIR: CERS (156M) vs XAIR (689K).
CERSXAIRCERS / XAIR
Capitalization343M79.9M429%
EBITDA-26.34M-67.06M39%
Gain YTD-17.593-75.14323%
P/E RatioN/AN/A-
Revenue156M689K22,642%
Total Cash65.9M31.3M211%
Total Debt96M16.9M568%
FUNDAMENTALS RATINGS
CERS vs XAIR: Fundamental Ratings
CERS
XAIR
OUTLOOK RATING
1..100
1565
VALUATION
overvalued / fair valued / undervalued
1..100
47
Fair valued
33
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9799
PRICE GROWTH RATING
1..100
6164
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XAIR's Valuation (33) in the null industry is in the same range as CERS (47) in the Medical Specialties industry. This means that XAIR’s stock grew similarly to CERS’s over the last 12 months.

XAIR's Profit vs Risk Rating (100) in the null industry is in the same range as CERS (100) in the Medical Specialties industry. This means that XAIR’s stock grew similarly to CERS’s over the last 12 months.

CERS's SMR Rating (97) in the Medical Specialties industry is in the same range as XAIR (99) in the null industry. This means that CERS’s stock grew similarly to XAIR’s over the last 12 months.

CERS's Price Growth Rating (61) in the Medical Specialties industry is in the same range as XAIR (64) in the null industry. This means that CERS’s stock grew similarly to XAIR’s over the last 12 months.

CERS's P/E Growth Rating (100) in the Medical Specialties industry is in the same range as XAIR (100) in the null industry. This means that CERS’s stock grew similarly to XAIR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CERSXAIR
RSI
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
83%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
85%
Momentum
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
87%
MACD
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
81%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
87%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
89%
Advances
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 18 days ago
83%
Declines
ODDS (%)
Bearish Trend 26 days ago
82%
Bearish Trend 3 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
73%
Bearish Trend 1 day ago
89%
Aroon
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
79%
View a ticker or compare two or three
Ad is loading...
CERS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XAIR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BRBR77.990.75
+0.97%
BellRing Brands
BAC46.08N/A
N/A
Bank of America Corp
CWCO25.57-0.28
-1.08%
Consolidated Water Co Ltd
SDGR21.07-0.69
-3.17%
Schrodinger
UNCY0.74-0.06
-7.44%
Unicycive Therapeutics

CERS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CERS has been loosely correlated with MASS. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if CERS jumps, then MASS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CERS
1D Price
Change %
CERS100%
-1.66%
MASS - CERS
49%
Loosely correlated
-6.19%
FLGT - CERS
45%
Loosely correlated
+0.55%
BNGO - CERS
44%
Loosely correlated
-1.91%
ICUI - CERS
42%
Loosely correlated
-0.36%
CRL - CERS
42%
Loosely correlated
+0.37%
More

XAIR and

Correlation & Price change

A.I.dvisor indicates that over the last year, XAIR has been loosely correlated with OPK. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if XAIR jumps, then OPK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XAIR
1D Price
Change %
XAIR100%
+0.95%
OPK - XAIR
35%
Loosely correlated
+1.26%
KIDS - XAIR
32%
Poorly correlated
-4.82%
SHWGY - XAIR
32%
Poorly correlated
-0.80%
CERS - XAIR
31%
Poorly correlated
-1.66%
IDXX - XAIR
31%
Poorly correlated
+0.02%
More